growing geriatric population is driving the Ophthalmoplegia Market
Technavio analyzes that the Ophthalmoplegia Market is expected to grow at a CAGR of 6% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 435.8 million.There are various factors that contribute to the growth of the market. The ophthalmoplegia market is experiencing significant growth due to the increasing geriatric population. With aging comes an increased prevalence of neurological disorders, including ophthalmoplegia. According to the World Health Organization, the global population aged 65 and above is projected to reach 1.5 billion by 2050. This demographic shift will undoubtedly fuel the demand for diagnostic and therapeutic solutions for ophthalmoplegia. Additionally, advancements in technology and research are leading to the development of more effective and less invasive treatments, further boosting market growth.
In the global ophthalmoplegia market, hospitals serve as the leading end-users due to their role as primary diagnostic and therapeutic centers for eye movement disorders. Equipped with advanced diagnostic tools such as clinical examinations, imaging studies, blood tests, electromyography (EMG), and biopsies, hospitals provide comprehensive patient care. Large hospitals, particularly tertiary care centers and academic medical institutions, manage complex ophthalmoplegia cases requiring multidisciplinary approaches and sophisticated treatments. These healthcare facilities offer various therapeutic interventions, including symptomatic management, surgical interventions, and rehabilitation services. The presence of specialized neurologists, ophthalmologists, and supporting medical staff enables hospitals to handle both acute and chronic ophthalmoplegia cases effectively.
Know which region is leading the market growth by requesting a sample report
Ophthalmoplegia Market Segmentation
As per our research findings, here are some of the key competitors that are leading the industry
Find out what is trending in the market by accessing the free PDF report
Ophthalmoplegia refers to the weakness or paralysis of the eye muscles, leading to impaired eye movement and misalignment. This condition can manifest as external ophthalmoplegia, affecting the muscles controlling eyelid movement and pupil constriction, or internal ophthalmoplegia, impacting the extraocular muscles responsible for lens adjustment and eye rotation. Causes include nerve damage from systemic conditions, muscle disorders, genetic mutations, and mitochondrial dysfunction. Diagnosis involves a multidisciplinary approach, including clinical examinations, imaging studies, blood tests, electromyography (EMG), and biopsies. Symptomatic management includes symptom relief through medication and surgical interventions, while addressing underlying causes can improve quality of life. Cranial nerves, including the oculomotor, trochlear, abducens, superior rectus, and inferior rectus, are commonly involved.
The global ophthalmoplegia market is a significant segment of the larger pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various types of drugs, including generics, non-generics, and veterinary medicines. According to Technavio's market analysis, the healthcare industry's overall size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The growth of the pharmaceuticals market is influenced by several key factors, such as the increasing aging population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old. This demographic shift will lead to a higher demand for treatments related to eye muscles, such as external and internal ophthalmoplegia, eye movement, pupil constriction, and lens adjustment.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
